Blog's

11th June

India Banking & Pharma Sector 2025: Growth Trends, Mutual Fund Opportunities, and Outlook

 

India’s banking sector and pharmaceutical industry are at the forefront of economic growth in 2025. With robust asset quality, surging credit demand, and world-class pharma exports, both sectors are attracting investors from India, Pakistan, and beyond. Here’s a deep dive into the latest performance, growth drivers, and top mutual fund opportunities.

 

Indian Banking Sector: Stronger Than Ever

Key Metrics (FY2024–25)

• Gross NPA Ratio (Sept 2024): 2.6% (12-year low)
• Net NPA Ratio (Sept 2024): 0.6%
• Capital Adequacy (CRAR): 16.7%
• Credit Growth: +12% YoY
• PSB Net Profit (FY25): ₹1.78 lakh crore (+26% YoY)
• UPI Payments (Mar 2025): ₹23 lakh crore

Performance Trends

Over the past decade, Indian banks have seen a dramatic improvement in asset quality and profitability. GNPA ratios have dropped from their 2017–18 peak to historic lows, while both public and private banks posted double-digit profit growth in FY2025. Deposit growth (10–11%) is keeping pace with lending, ensuring liquidity.

Digital banking is booming-UPI payments hit record highs, and fintech innovations are reshaping customer experience. The RBI’s Financial Inclusion Index rose from 53.9 (2021) to 64.2 (2024), showing wider access to banking services.

Growth Drivers

• GDP growth projected at 6.3–7% through 2026
• Government focus on infrastructure, MSME, and retail lending
• Rising incomes and rural recovery boost demand for personal and SME loans
• Fintech and NBFC penetration mobilize savings and lending
• Strong capital markets and insurance sector growth
• Consolidation and improved governance among PSBs

Outlook & Forecasts

Analysts expect steady credit growth (12–14% range) in the near term. CARE and Crisil forecast bank credit growth at 13% in FY26. With inflation moderating and repo rates stable, lending rates may ease, supporting further expansion. SEBI-regulated reports suggest the banking sector could double over the next decade.

Challenges & Catalysts

• Maintaining asset quality in a higher-rate environment
• Margin pressures from regulated savings rates
• Cybersecurity risks amid digital expansion
• Further reforms (NBFC-bank linkages, differentiated licenses)
• New National Finance Commission for climate and development

 

Mutual Fund Opportunities: Banking Sector

Investors can tap into India’s banking boom via sectoral mutual funds. Top funds include:

• SBI Banking & Financial Services Fund (AUM: ₹7,650 Cr)
• UTI Banking & Financial Services Fund
• Kotak Banking Sector Fund
• HDFC Banking & Financial Services Fund

These funds track banking indices like Nifty Bank and offer focused exposure to the sector. Broader financial sector funds and banking ETFs are also available. (Note: sectoral funds carry higher risk and cyclicality.)

 

Indian Pharmaceutical Sector:

Key Metrics

• Market Size (2023): US$41 billion (3rd largest by volume)
• Global Generic Supply: 20% by volume
• Global Vaccine Supply: 62%
• Pharma Exports (FY2020): ~$16.3 billion

Performance Trends

India’s pharma sector weathered the pandemic well, with domestic sales growing 8–10% annually. Exports are surging as global supply chains diversify. R&D spending is up, and India leads the world in biosimilar approvals.

The API market is sizable (~US$22.5B in 2024), but 72% of API imports are from China. The government’s PLI scheme (₹15,000 Cr outlay) is boosting high-value drug manufacturing and reducing import dependence.

 

Growth Drivers

• Large, aging population and rising chronic disease burden
• Expanding healthcare access and insurance (Ayushman Bharat)
• Push for Atmanirbhar Bharat in pharmaceuticals
• Global demand for affordable generics and biosimilars
• Government incentives and regulatory reforms

Outlook & Forecasts

Industry bodies forecast the pharma market to reach US$120–130 billion by 2030, and possibly $400B+ by 2047. Exports could more than double by 2030. India is poised to become a global leader in generics, APIs, and biosimilars.

Challenges & Catalysts

• API import dependence (efforts to boost local production ongoing)
• Regulatory compliance (USFDA/WHO inspections)
• Pricing pressure from the National List of Essential Medicines
• Global competition (Western and Chinese firms)
• Ongoing reforms in drug pricing, FDI, and clinical trial frameworks
• Health-tech integration (telemedicine, digital health records)

 

Mutual Fund Opportunities: Pharma & Healthcare

For investors, pharma and healthcare sector funds offer exposure to this growth story. Leading options include:

• SBI Healthcare Opportunities Fund (AUM: ₹3,670 Cr)
• UTI Healthcare Fund
• ICICI Prudential Pharma Healthcare and Diagnostics Fund

These funds invest in pharmaceutical, biotech, and healthcare stocks, and can outperform during sector upcycles. (Caution: sectoral funds are volatile and best for tactical allocation.)

 

Conclusion: Diversified Growth, Strong Investment Potential

India’s banking and pharma sectors are set for sustained growth through 2025 and beyond. With robust fundamentals, policy support, and digital innovation, both sectors offer compelling opportunities for investors in India and Pakistan. Sectoral mutual funds provide a focused way to participate in these trends, but are best used as part of a diversified portfolio.

 

Read More